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Abstract
Although the sequence variable loops of the human immunodeficiency virus’ (HIV-1) surface envelope glycoprotein (gp120)
can exhibit good immunogenicity, characterizing conserved (invariant) cross-strain neutralization epitopes within these
loops has proven difficult. We recently developed a method to derive sensitive and specific signature motifs for the three-
dimensional (3D) shapes of the HIV-1 neutralization epitopes in the third variable (V3) loop of gp120 that are recognized by
human monoclonal antibodies (mAbs). We used the signature motif method to estimate the conservation of these epitopes
across circulating worldwide HIV-1 strains. The epitope targeted by the anti-V3 loop neutralizing mAb 3074 is present in
87% of circulating strains, distributed nearly evenly among all subtypes. The results for other anti-V3 Abs are: 3791, present
in 63% of primarily non-B subtypes; 2219, present in 56% of strains across all subtypes; 2557, present in 52% across all
subtypes; 447-52D, present in 11% of primarily subtype B strains; 537-10D, present in 9% of primarily subtype B strains; and
268-D, present in 5% of primarily subtype B strains. The estimates correlate with in vitro tests of these mAbs against diverse
viral panels. The mAb 3074 thus targets an epitope that is nearly completely conserved among circulating HIV-1 strains,
demonstrating the presence of an invariant structure hidden in the dynamic and sequence-variable V3 loop in gp120. Since
some variable loop regions are naturally immunogenic, designing immunogens to mimic their conserved epitopes may be a
promising vaccine discovery approach. Our results suggest one way to quantify and compare the magnitude of the
conservation.
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Introduction
The gp120 surface envelope glycoprotein of HIV-1 (HIV) is the
primary target for antibodies that neutralize HIV infection in vitro
[1], and passive transfer of HIV gp120-specific antibodies confers
protection from HIV and chimeric simian-human immune
deficiency virus (SHIV) challenge in several animal models [2–
8]. Furthermore, some highly sequence variable regions of gp120
are strongly immunogenic [9–13], and are documented to make
up a proportion of the serum neutralizing antibody response to
immunization with gp120 [14]. Unfortunately, extraordinary
antigenic diversity is a hallmark of the HIV Group M strains
that are causing the acquired immune deficiency syndrome (AIDS)
pandemic, and this diversity is especially prominent in the
sequence variable regions, including the V3 loop [15].
One of the most productive approaches to interrogating the
antigenic diversity of HIV viruses for conserved shapes that may
be immunologically targeted is to isolate monoclonal antibodies
from HIV-infected human subjects and study their specificities,
specifically their ability to neutralize in vitro infection by diverse
HIV viruses. For example, two constant regions in gp120 and
gp41, the CD4 binding site (CD4bs) of gp120 and the membrane
proximal external region (MPER) of gp41, have been the subject
of much study, primarily because they are targeted by three
broadly neutralizing human mAbs, b12, 2F5 and 4E10. However,
the breadth, potency and activities of the hundreds of variable-
loop-specific monoclonal antibodies (mAbs) isolated from HIV-
positive subjects varies widely, as expected given the antigenic
diversity in these regions [16,17]. Many such mAbs are non-
neutralizing, as expected. Among those with neutralizing activities,
many are strain- or type-specific [18], while others display
neutralizing activity across subtypes [19–23], including anti-V3
loop mAbs, which show some of the broadest patterns [24,25].
Accordingly, the variable loops, and the V3 loop in particular,
have been considered improbable targets for vaccine-induced
protective antibodies [26], despite the observed immunogenicity
advantages and despite extensive evidence that there is a great deal
of immunologic cross-reactivity among V3 loops from diverse
strains and clades [27–29].
Antibody epitopes are traditionally defined immunochemically
via epitope-mapping experiments using nested sets of linear
peptides or libraries of mutated antigens, but this approach cannot
be translated to easily measure the conservation of epitopes across
the informatics of the large number of circulating HIV-1 strains.
We previously approached the problem from a purely 3D
structural point of view in order to achieve the translation of
vaccine-relevant molecular features to clinically relevant informat-
ics observations (viral sequences). In the 3D structural view,
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on the surface of an antigen that is evident in the crystal structure
of an Ab:epitope complex. We showed we could work back to the
viral sequence from the 3D structure of the Ab:epitope complex
and define a specific signature motif for the epitope recognized by
the mAb that is evident simply by viewing any HIV-1 gp120
sequence [30]. This prototype method was applied to mAbs 447-
52D and 2219 from the crystal structures of these mAbs
complexed with V3 loop peptides and demonstrated that
pseudoviruses with sequences containing the epitope signature
motifs are highly sensitive to the mAbs targeting that motif, while
those lacking the motifs were poorly sensitive to neutralization.
The prior results demonstrated that the signature motifs were
highly sensitive and specific for neutralization epitopes, and that
the motifs could be used to search the HIV compendium to
estimate the conservation of the 2219 and 447-52D epitopes across
all circulating HIV-1 strains. One important aspect of this finding
was that the motifs were sensitive and specific for epitopes
displayed by viruses tested in vitro, so the use of the motifs
incorporates the wide range of flexibilities exhibited by different
V3 loop sequences.
Additional structures of novel anti-V3 mAbs isolated from HIV-
positive patients have recently become available, including
structures for 2557 [31], 3791 (unpublished data), 3074 [31],
268 [31] and 537-10D [32], along with more recent WHO data
on the subtype classification of circulating HIV-1 strains [33]. We
used these new data to estimate the range of conservation of
neutralization epitopes targeted by a diversity of anti-V3 mAbs.
Materials and Methods
3D-structure-based sequence motifs for neutralization epitopes
were derived as previously described [30], including neutralization
assays of diverse chimeric pseudoviruses demonstrating the
specificity of each mAb for viruses displaying their cognate motif
(data not shown). For mAbs 3074 [31], 2557 [31], 3791 (X-P
Kong, personal communication), 537 [32], and 268 [31], the
motifs were derived from crystal structures of these mAbs
complexed with various V3 loop peptides (Table 1).
Briefly, a signature motif for an epitope is generated via
examination of sequence-specific atomic contacts in a co-crystal
structure between the monoclonal antibody (mAb) and a bound
peptide’s side chain atoms (Examples for mAbs 3074, 2557 and
268-D are shown in Figure 1). Only contacts in which the side-
chain is largely buried in a pocket on the mAb molecular surface
are included in the motif, as these were shown in the previous
study [30] to be neutralization-specific. Any mAb contacts with
peptide main-chain atoms are not included in the motif, as these
are not sequence (side-chain) specific, and viral escape mutations
that change the side chain will not necessarily alter the backbone
or the mAb interaction. Side-chain contacting, but not buried in,
the antibody molecular surface were shown by the previous study
not to correlate with neutralization sensitivity (although they may
still influence antibody binding). Where a strong (buried) side-
chain contact is observed, an amino acid alphabetical letter is
added to the signature motif. For example, the constraint ‘‘H13’’
would indicate that a His at position 13 is a necessary part of the
neutralization epitope. Each motif was refined further by
considering which amino acid side chains could substitute
energetically at each key side-chain-buried contact locations
identified as part of the motif. Only side chain substitutions
occurring naturally in the viral population in more than 4% of
recorded viruses were sampled at each position (data for positional
variation was extracted from the Los Alamos National Laboratory
(LANL) HIV Sequence Database, February, 2010, http://hiv.lanl.
gov). Within a crystal structure of the Ab:V3-peptide complex the
side chain in question was energetically minimized and the final
energy recorded. The side chain was then in silico modified to a
new side chain and energetically minimized and the new energy
recorded. If the energy score of the substitution was within 1.5 of
the native side-chain, the substitution was considered as
energetically silent (non-disruptive). Such energetically silent
substitutions were included in the motif even though they were
not derived directly from the crystal structure.
For clarity, we used standard V3 loop numbering for the most
common length of 35 residues of the V3 loop throughout this
study. These numbers correspond to the standard HXB2
coordinate system as follows: HXB2 amino acid 296 is the same
cysteine as position number 1 of the standard V3 loop; HXB2
amino acid 315 is the same as position 18 of the standard V3 loop.
Starting from these structure-based signature sequence motifs,
the estimates of worldwide epitope coverage were determined
using the steps described in our previously published method [30],
modified with the latest 2004 epidemiological and sequence data
available from Hemlaar, et. al. [33], while previously we used data
derived by Osmanov et al. in 2002 [34]. Hemlaar et. al. collected
three times as many samples as Osmanov et. al., included data
from more countries, and collected data from more than one
genome segment for subtyping, which provides valuable insight
Table 1. Sequence Motifs for Epitopes Targeted by Individual anti-V3 mAbs Derived from 3D Structures of mAbs:V3 Complexes.
mAb
Infecting Donor HIV
Subtype
V3 Loop Viral Peptide Bound to mAb in Crystallographic
Complex (Superscript indicates V3 loop numbering from
beginning to end of epitope area bound by mAb in the
structure)
Sequence Motif for Epitope (Superscript
indicates V3 loop numbering)
268-D B MN (R
10KRIHIGPGR
18AFA)
10[R,K]xx[H,R]xxPxR
18
447-52D B MN (KRIHIG
16PGR
18A)
16PxR
18
537-10D B MN (
9RKRIHIGPGR
18AFYAT)
9Rxxxx[I,M]xPxR
18
2219 B MN (K
9RKRIHIGPGRAFY
21TTKNA)
9RKx[I,V]xxxxxxxx[Y,F]
21
2557 CRF02_AG NY5 (TK
10KGIAIGPGRTLY
21)
10Kx[I,V]xxxxxxxxY
21
3074 CRF02_AG VI13041 (ATRKGIH
14IGPGRAF
20YA)
14[I,L,M]xPxxx[F,W]
20
3791 C CA7 (R
11SIRIGSGQ
18TSYATGA)
11SxRIxxxQ
18
Infecting Donor HIV Subtype indicates the subtype of the virus infecting the patient from which the mAb was isolated. V3 loop numbering is as described in the
Methods. ‘‘x’’ in the sequence motifs indicates that any amino acid may occupy that position.
doi:10.1371/journal.pone.0015994.t001
V3 Loop Epitope Conservation Scores
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version of the LANL HIV Sequence Database (February, 2010,
http://hiv.lanl.gov) for the results reported in this study.
Results
The 3D contact surface for each V3 peptide with each
neutralizing mAb was carefully examined to derive the signature
motif for the neutralization epitope as described in the Methods.
In each case, V3 loop amino acid positions making contact with
the mAb only through their backbone atoms were deemed tolerant
positions and not included in the sequence motif, whereas a
contact between the V3 peptide and the mAb characterized by
partial burial of the V3 side chain into the molecular surface of the
mAb was deemed an intolerant position that corresponds to a
defined amino acid letter in the sequence motif. Examples of the
key buried V3 loop side chains from this analysis are shown in blue
stick depiction in Figure 1 for three of the antibodies 3074, 2557
and 268-D. The 3074:V3 molecular interface is characterized by
one hydrophobic side-chain (Ile14) from the N-terminal b-strand
and one hydrophobic side-chain from the C-terminal b-strand
(Phe 20) of the V3 loop crown clustered together at the center of a
twisted b-hairpin and buried in a central hydrophobic pockets on
the mAb surface (Figure 1A). The proline at position 16 of the V3
loop is also buried in the mAb molecular surface. These three side
chains cannot vary significantly without disrupting the complex,
but side-chains at all other positions can vary without significantly
disrupting the complex. Thus, only viral escape mutations at I14,
P16 and F20 can disrupt neutralization mediated by 3074, while
sequence variation elsewhere in the V3 loop leaves the interaction
unaffected. The sequence motif for the predicted epitope targeted
by mAb 3074 is therefore ‘‘I
14-x-P
16-x-x-x-F
20’’ using V3 loop
numbering. Inspection of the bioinformatics variation patterns at
the positions 14, 16 and 20 revealed that besides Ile, Pro and Phe,
observed at these positions in the crystal structure, Leu and Met at
the position 14 and Trp at the position 20 occurred in more than
4% of recorded viruses. Modeling showed that Leu and Met
substitutions for Ile at position 14 and Trp substitution for Phe at
position 20 are energetically silent (see Methods and Figure 2 for
details). In this way, a specific motif ‘‘[I, L, M]
14-x-P
16-x-x-x-[F,
W]
20’’ for the 3074-targeted epitope was derived from the 3D
structure of the mAb-viral peptide complex shown in Figure 1A.
The corresponding structures for 2557 and 268-D are shown for
comparison.
Our prior work demonstrated that the epitope motifs derived by
the above method are sensitive and specific predictors of in vitro
neutralization of a diverse set of viruses [30]. The sequence motif
derived from the crystal structure of the Ab:antigen complex for the
neutralization epitope targeted by mAb 3074 is unique from the
other six motifs (Table 1), therefore we can infer that this motif is a
unique signature motif for the neutralization epitope targeted by
mAb 3074. A similar analysis was performed for all the seven mAbs
we considered with available V3:mAb crystallographic structures to
identify a library of unique signature motifs for the neutralization
epitopes targeted by all seven anti-V3 mAbs (Table 1).
Overall, the motifs for the Abs are diverse and overlap along the
V3 loop crown sequence (Table 1). 2219 and 2557 only engage
side chains in the N- and C-terminal strands and are not restricted
by amino acid substitutions in the V3 crown b-turn. 268-D, 537-
10D, 447-52D, 3791 and 3074, on the other hand, all engage the
Figure 1. mAb 3074, 2557, and 268-D bound to V3 loop
peptides. (A) Structure of mAb 3074 (grey molecular surface) bound to
a peptide (red ribbon and blue stick depiction) with the same sequence
as the crown of the V3 loop of subtype AG isolate VI191. (B) Structure of
mAb 2557 (grey molecular surface) bound to a peptide (red ribbon and
blue stick depiction) with the same sequence as the crown of the V3
loop of subtype B isolate NY5. (C) Structure of mAb 268-D (grey
molecular surface) bound to a peptide (red ribbon and blue stick
depiction) with the same sequence as the crown of the V3 loop of
subtype B isolate MN. The side-chains of the V3 peptide that are buried
in the molecular surface of the mAb are colored blue and labeled.
doi:10.1371/journal.pone.0015994.g001
V3 Loop Epitope Conservation Scores
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and the others mostly restricted by the Q/R at position 18.
Interestingly, only the motifs for 447, 537 and 268 are mutually
exclusive with another mAb neutralization epitope (3791) since the
former requires an Arg (R) at position 18 of the V3 loop and the
latter requires a Gln (Q) at the same position. The other motifs
may occur simultaneously in the same V3 loop. The motifs for
neutralization epitopes targeted by 2219 and 2557 differ by only
one position, despite the fact that these mAbs derive from subjects
infected with viruses belonging to different subtypes.
Figure 2. Results of the in silico modeling of amino acid substitutions in V3 loop epitopes. For each mAb epitope resolved
crystallographically, in silico substitutions were made to the structure of the complex, the perturbation of the change was minimized
conformationally and the change in energy of the complex was calculated as described in the Methods (right column). Only amino acid substitutions
occurring naturally in the viral population in more than 4% at each position were considered in the study. Red colored values indicate energetically
silent or non-disruptive substitutions that retained a similar mAb contact and which were then added to the motif describing the epitope. *One
change resulted in energetic improvement but a conformational change such that contact with the mAb was lost, thus not contributing to the motif.
doi:10.1371/journal.pone.0015994.g002
V3 Loop Epitope Conservation Scores
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neutralization epitopes by searching for the rate of occurrence of
their motifs in each subtype in the LANL HIV Sequence Database
(http://hiv.lanl.gov), weighting the percent occurrence by each
subtype’s proportional contribution to circulating HIV strains
actually in the human population as estimated by the Hemelaar et
al. WHO study, and adding up the total (Table 2 and Methods).
mAb 3074’s epitope is found in 87% of circulating HIV-1 strains
infecting humans, with a significant rate of occurrence in strains
from all the major subtypes. mAb 3791 is largely subtype C
restricted, but because this subtype represents 50% of the disease
pandemic, the neutralization epitope targeted by 3791 is estimated
to be conserved in 63% of circulating strains worldwide. mAbs
2219, a subtype B derived mAb, and 2557, a non-subtype B
derived mAb, are conserved in 56% and 52% of circulating strains
worldwide, and are relatively evenly conserved across the major
subtypes. Interestingly, the neutralization epitope 447-52D—
perhaps the most cited anti-V3 mAb in the literature—is estimated
to be present in only 11% of circulating strains and is highly
restricted to subtype B. Finally, the neutralization epitopes
targeted by 537-10D and 268-D follow a similar pattern to
that for 447-52D: less than 10% conservation in circulating
worldwide strains, and predominantly appearing in subtype B
strains.
While some predicted anti-V3 loop mAb neutralization epitopes
appear to be largely restricted to a single subtype (268, 447-52D to
subtype B, for example), several are evenly conserved across all
major subtypes (3074, 2219, 2557; Figure 3). Indeed, although
3791’s predicted neutralization epitope is largely restricted to
subtype C, its overall prevalence (63%) is greater than that of 2219
(56%) or 2557 (52%), whose epitopes are distributed more evenly
across the subtypes.
These subtype distribution patterns correlate with recent studies
measuring the neutralization of viruses from different subtypes by
these mAbs. Although it is difficult to extrapolate the diversity of
less than 100 viruses tested in neutralization assays to the diversity
of the 10 s of thousands of viruses circulating in the world, the
subtype distribution of our informatics assessment clearly corre-
lates with the subtype distribution of the in vitro tests (Table 3). For
example, in the in vitro panel of viruses, mostly subtype B viruses
are neutralized by mAb 447-52D and this is concordant with the
appearance of its cognate epitope mostly in subtype B viruses
worldwide.
Discussion
The conservation of different predicted neutralization epitopes
targeted by anti-V3 loop antibodies across circulating HIV-1
strains varies widely according to this study, but some highly
conserved individual neutralization epitopes are indeed present in
this immunodominant, sequence variable region. Epitope conser-
vation ranged from ,5% of known HIV viruses for the motif
recognized by mAbs such as 268 to 87% for the motif recognized
by mAbs such as 3074 (Table 2). The result for mAb 447-52D
mirrors an earlier study, but in this updated version, the estimate
of 2219 conservation is higher than in the previous study [30]. The
relative conservation patterns estimated in this study via
informatics are consistent with recent in vitro neutralization studies
showing that 2219, 2557 and 3074 neutralize a large fraction of
diverse viruses carrying pseudotyped envelopes from HIV subtypes
A, B, C and D [35]. This means that testing a mAb against a
diverse panel of viruses or defining the epitope by our method
might independently assess the disease-specific breadth of a mAb
at low resolution. Both estimates should be concordant in terms of
subtype breadth, as they are for these mAbs, for either to be a
reliable as a ‘‘broad neutralization score’’ for an mAb or an
epitope: indeed, the concordant combination of the two connects
molecular in vitro neutralization results using a small viral panel
with worldwide clinical bioinformatics recordings of HIV-1
antigenic diversity.
The observed conservation of 3074, 2219 and 2557 epitopes
despite their location in a sequence variable loop is also consistent
with findings that mAbs targeting compound quaternary neutral-
izing epitopes composed of V2 and V3 can neutralize pseudo-
viruses carrying the envelopes of primary isolates from diverse
subtypes[36]. Conserved epitopes are thus hidden in the
immunogenic sequence variable loops of gp120, but the challenges
are finding them, assessing the magnitude of their conservation
and exploiting them in immunogen design. This study provides a
tool for addressing the second of these three challenges.
Our results show that clusters of circulating viruses defined by
the presence of a particular mAb epitope do not consistently
correlate with the clusters of viruses defined phylogenetically by
subtype (Figure 3). This is not a surprising finding given that the
whole viral genomic sequence determines the subtype while as
little as one amino acid in the sequence may define an epitope.
However, the demonstration of this divergence in our results calls
Table 2. Fraction of Circulating HIV Strains Worldwide That Contain the Sequence Motifs for anti-V3 mAb Epitopes.
mAb
Subtype A
(12%)
Subtype B
(10%)
Subtype C
(50%)
Subtype D
(3%)
Subtype G
(6%)
Subtype
CRF01_AE
(5%)
Subtype
CRF02_AG
(5%) Total (100%)
3 0 7 4 1 1 84 8 13458 7
3 7 9 1 704 5 01136 3
2 2 1 9 673 0 04035 6
2 5 5 7 672 7 04035 2
4 4 7 - 5 2 D 17010101 1
5 3 7 - 1 0 D 06010109
2 6 8 - D 04000005
The column headings for each of the subtypes displays the subtype name and, in parentheses, the percentage of the whole set of worldwide circulating viruses that
belong to that subtype. Each cell shows the percentage of worldwide viruses, all of that subtype, that contain the sequence motif targeted by the indicated mAb of that
row: thus ‘‘11%’’ for 3074 and subtype A indicates that 11% of the 12% of worldwide viruses that are subtype A contain the 3074 targeted epitope. Each cell in the Total
column indicates the percentage of worldwide circulating viruses that contain the signature motif of the epitope targeted by the indicated mAb of that row.
doi:10.1371/journal.pone.0015994.t002
V3 Loop Epitope Conservation Scores
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describe certain mAbs, when the use of the term is based solely on
the ability of the mAb to neutralize multiple viral subtypes. The
conceptual flaw in this assumption is easily seen via reductio ad
absurdum: a mAb targeting an epitope present in only 5 viruses each
from a different subtype would be considered extremely broad in
terms of its breadth across subtypes by the prevailing definition,
but would in reality have essentially no neutralization/antigenicity
range among globally circulating HIV viruses. In practice, our
results show that the assumption of antigen-type/genotype
equality is somewhat unreliable: mAbs 2219, 2557 and 3074,
whose epitopes appear independently of subtype, also occur quite
widely in circulating viruses. However, the assumption that
neutralizing only one subtype equates with disease irrelevance
should be made with caution: 3791 is almost completely subtype C
restricted, but because subtype C is such a large proportion of
circulating viruses, protection against this epitope may be highly
disease relevant in certain epidemic areas and globally would
represent 63% of circulating viruses.
Specifically, our results call into question any extrapolation of
results with 447-52D to characterization of the overall antigenicity
of the V3 loop. 447-52D is commonly used in the literature to
represent the activity of anti-V3 mAbs, but our results show that its
neutralization epitope is only present in 11% of circulating viruses
Figure 3. Radar graphs illustrating the data on the global cross-HIV-1-strain conservation neutralization epitopes targeted by
mAbs. The mAb is indicated in black bold letters above its graph. Each radar graph is a polygon, each point of which is representative of each subtype
and each axis of which is proportional to the fraction of that subtype in the whole set of circulating worldwide strains. Thus the point labeled ‘‘C’’ is
subtypeCanditsaxisfromthecenterofthepolygonisaslongasalltheotheraxescombined,becausesubtypeCrepresentshalf(50%)oftheworldwide
population of viruses. Thepercentage of each subtype that contains the neutralization epitope targeted by the mAb is plotted on each axis. Connecting
each one of these plotted points traces out an inner polygon colored red that is visually representative of the population of circulating viruses that
containthesequencemotiffortheneutralizationepitopetargetedbythatmAb.Thus,ifmostoftheareaenclosedbythepolygoniscoloredred,mostof
the circulating HIV-1 viruses in the human population worldwide contain the epitope targeted by the indicated mAb in their sequences.
doi:10.1371/journal.pone.0015994.g003
Table 3. Fraction of HIV-1 Pseudoviruses of five subtypes Neutralized by anti-V3 mABs.
mAb Subtype A (11 psVs) Subtype B (51 psVs) Subtype C (24 psVs) Subtype D (10 psVs)
Subtype CRF02_AG (2
psVs)
3 0 7 4 1 82 24 61 01 0 0
2 2 1 9 1 84 92 91 00
2 5 5 7 1 84 72 11 01 0 0
447-52D 9 47 4 10 0
Summary of neutralization breadth of individual mAbs from previously published experiments. The column headings for each of the subtypes displays the subtype
name and the number of HIV-1 pseudoviruses of that subtype tested for neutralization by the indicated anti-V3 mAbs. Each cell shows the percentage of tested HIV-1
pseudoviruses which are neutralized by the indicated mAb of that row. The in vitro neutralization data from Hioe et al. [35] was summarized in this table.
doi:10.1371/journal.pone.0015994.t003
V3 Loop Epitope Conservation Scores
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representative mAb (Figure 3). Indeed, our results and recent
studies of 447-52D neutralization of diverse panels of viruses show
that it is subtype B restricted [17,35]. Thus, conclusions based on
observations with 447-52D, which are the most numerous in much
of the literature invoking anti-V3 mAbs, are really only applicable
to HIV phenomenology in North America and Europe and ignore
the significant contribution of subtype C to the pandemic,
estimated at half of all circulating viruses. In reality, our study
shows that the distributions of epitopes targeted by individual anti-
V3 mAbs are quite variable, so no single mAb is representative of
V3 loop antigenicity.
The sequence motifs for the neutralization epitopes targeted by
mAbs 2219 and 2557 were found to be very similar, despite the
fact that they were derived from the cells of two different
individuals, infected with different virus subtypes (B and
CRF02_AG, respectively) from two different geographic regions
(North America and Africa, respectively) [24,29]. Thus, despite
originating from infections with very different viruses in very
different global locations, the neutralization epitopes of these two
mAbs are very similar both in structure and in distribution.
From a technical point of view, while our studies have shown
that the signature motifs are highly accurate, they are dependent
on our as-yet-imperfect method for defining which amino acid can
substitute at the key sites in the motif based on energetic/modeling
studies on the crystallographic structural data, without accounting
for the insertions and deletions that rarely occur in the V3 loop.
Studies correlating these modeling approaches with additional
pseudovirus neutralization measurements may improve the
precision of the motifs marginally.
These results have several implications for HIV vaccine design.
This study only reports results based on the physical presence of
antibody-targeted epitopes in HIV viruses. The physical presence
of an epitope in an HIV virus does not equate to neutralization of
the virus or immunogenicity of the epitope. Epitopes in gp120 are
well known to be differentially masked by glycans or occlusion by
other protein regions [37–39]. This is true for V3 loop
neutralization epitopes as well [40]. The finding reported in this
study is a crucial step in attempting to characterize masking:
viruses that can be ascertained to contain epitopes by the methods
reported here that are not neutralized by the cognate mAbs in
vitro necessarily mask those epitopes. Thus, by combining our
approach with in vitro monoclonal antibody-mediated neutraliza-
tion assays, masking of specific mAb targeted epitopes can be
precisely characterized. Epitope masking is expected to be the
major factor reducing the practical cross-strain neutralization
value of any given conserved anti-variable-loop epitope from its
theoretical maximal cross-strain reactivity to its practical cross-
strain reactivity expected for a vaccine.
Other factors influence neutralization even when the epitope is
present and not masked. For example, dynamic tertiary folding of
the V3 loop in a particular strain may disrupt the epitope despite
presence of the key side chains. This phenomenon may manifest
itself as variable affinity of anti-V3 mAb even for viruses in which
the V3 loop is exposed and accessible. Nevertheless, there is an
extensive literature showing that anti-V3 mAbs can neutralize up
to 55% of primary isolates [28,41–43]. Thus, neutralization
epitopes in the V3 loop are not ‘‘cryptic’’ in all viruses, and V3
masking is not an all-or-none phenomenon [44]. Moreover, it has
previously been shown that the exposure of V3 can be induced
and or enhanced by various gp120 ligands such as CD4 [45,46]
and anti-CD4bs [47] and anti-V2 Abs [48]. Targeting certain
conserved variable loop epitopes, such as 3074, 2219, 2557 and
3791, for immunogen design takes advantage of the immunodo-
minance of these regions, and the resulting immune serum might
well be broadly, not narrowly, effective even in the presence of
masking. Immunogenicity of an epitope is a function of its physical
presence in the virus, how masked it is in the virus, and human
immunologic factors. With this study, the first of these factors can
be controlled so that studies to characterize masking and, in turn,
immunogenicity of specific epitopes can be pursued with
observational clarity.
Our estimates of the extent and epidemiological boundaries of
the conservation of mAb-defined neutralization epitopes may be
useful in polyvalent HIV neutralizing antibody vaccine design, as
they provide a means to ‘‘see through’’ the diversity of molecular
configurations of the HIV envelope present in circulating viruses.
The method we have described provides a means to precisely
observe the occurrence of the 3074 epitope, for example, within
any envelope molecular configuration, and indeed within all
configurations at the same time (Figure 3). ‘‘Reverse vaccinology’’
strategies start from interesting neutralizing mAbs and work
backwards to design immunogens mimicking the neutralization
epitopes targeted by the mAbs. The selection of which variable
loop targeted mAb to mimic using these strategies is now
simplified by this approach: mAbs such as 3074 targeting highly
conserved epitopes are now easily distinguishable from less
prevalent mAbs such as 447-52D (Figure 3) to enhance the
neutralization information emerging from testing of the mAbs
against small panels of viruses. The motifs we have described can
be used to precisely partition viruses, separating those that contain
the neutralization epitope from those that do not contain the
neutralization epitope. The latter, of course, are unlikely to be
neutralized by the antibody. Immunogens designed to elicit
specific antibodies can thus be combined into a vaccine on the
basis of minimal or maximal overlap of sets of circulating viruses.
For example, two immunogens designed to elicit 447-52D and
3791 antibodies respectively would target two completely different
sets of circulating strains (in subtypes B and C respectively), so
their effects may be complementary. Conversely, two immunogens
designed to elicit 2219 and 2557 would reinforce each other in
targeting the same set of circulating viruses. Multiple rational
combinations are possible using the motifs.
Finally, although exploiting the epitope characterization
technology described here to elicit a specific antibody response
in animals is a challenge, recent DNA-prime and V3 loop protein
boost immunofocusing strategies were successful in exploiting the
immunodominance of the V3 region and stimulating robust cross-
strain neutralizing animal serum responses targeted to the V3
loop [49,50]. This suggests that the natural immunogenicity of
variable loop regions is indeed a window of opportunity in HIV
vaccine design, and the global conservation approach described
here for V3 loop neutralization epitopes may be immediately
useful for solving the ‘‘broad neutralization’’ problem of these
regions by identifying promising variable loop targeted mAb,
suchas 2219, 2557, 3791 and 3074, for ‘‘reverse-vaccinology’’
approaches.
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